Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with rheumatoid arthritis (RA) was associated with ...
1. Management of pediatric ulcerative colitis with tofacitinib successfully induced corticosteroid-free remission in 16% of patients at week 8 following ...
1. Dupilumab treatment for bullous pemphigoids resulted in improved clinical symptoms. 2. Patients with anti-BP180 antibody levels of at least ...
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
1. Treatment with biologics in pediatric patients with moderate to severe psoriasis was significantly associated with greater reduction in psoriasis ...
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial 1. Study findings suggest that early administration ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.